AI Insight
Clinical guidelines typically recommend coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI) for patients with left main coronary artery disease. However, a meta-analysis of four randomized controlled trials found that PCI was not associated with significantly higher all-cause mortality risk at 5 years compared to CABG. Long-term data from the PRECOMBAT and SYNTAX trials showed no significant mortality differences between PCI with first-generation drug-eluting stents and CABG at 10 years.
Why it matters
These findings challenge current clinical practice guidelines and suggest that PCI may be a viable alternative to CABG for left main coronary artery disease in selected patients. This could expand treatment options and allow for more personalized decision-making based on individual patient characteristics and preferences.
Understand the Science
Clinical guidelines generally favour coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI) as the revascularisation strategy of choice in patients with left main coronary artery disease.1–2 An individual patient-level meta-analysis of four randomised controlled trials comparing PCI with CABG has suggested that PCI was not associated with a significantly higher risk of all-cause mortality at 5 years.3 The PRECOMBAT trial4 and SYNTAX Extended Survival trial5 similarly demonstrated no significant differences in all-cause mortality at 10 years between patients who underwent PCI with first-generation drug-eluting stents and those who underwent CABG.
Source: [Comment] Left main coronary artery disease: PCI or CABG for revascularisation strategy